[{"category":"Human","name_of_medicine":"Hetlioz","ema_product_number":"EMEA/H/C/003870","active_substance":"tasimelteon","international_non_proprietary_name_common_name":"tasimelteon","therapeutic_area_mesh":"Sleep Disorders, Circadian Rhythm","atc_code_human":"N05CH","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Vanda Pharmaceuticals Netherlands B.V.","post_authorisation_procedure_status":"Re-examination","post_authorisation_opinion_status":"Negative","post_authorisation_opinion_date":"11/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"03/07/2015","first_published_date":"12/12/2025","last_updated_date":"19/12/2025","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/hetlioz"},{"category":"Human","name_of_medicine":"Recarbrio","ema_product_number":"EMEA/H/C/004808","active_substance":"imipenem monohydrate;cilastatin sodium;relebactam monohydrate","international_non_proprietary_name_common_name":"imipenem;cilastatin;relebactam","therapeutic_area_mesh":"Gram-Negative Bacterial Infections","atc_code_human":"J01DH56","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Merck Sharp & Dohme B.V. ","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"11/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"13/02/2020","first_published_date":"12/12/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/recarbrio"},{"category":"Human","name_of_medicine":"Aspaveli","ema_product_number":"EMEA/H/C/005553","active_substance":"pegcetacoplan","international_non_proprietary_name_common_name":"pegcetacoplan","therapeutic_area_mesh":"Hemoglobinuria, Paroxysmal","atc_code_human":"L04AJ03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"Yes","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Swedish Orphan Biovitrum AB (publ)","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"11/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"13/12/2021","first_published_date":"12/12/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/aspaveli"},{"category":"Human","name_of_medicine":"Simponi","ema_product_number":"EMEA/H/C/000992","active_substance":"golimumab","international_non_proprietary_name_common_name":"golimumab","therapeutic_area_mesh":"Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Arthritis, Rheumatoid","atc_code_human":"L04AB06","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Janssen Cilag International NV","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"11/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"01/10/2009","first_published_date":"12/12/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/simponi-0"},{"category":"Human","name_of_medicine":"Vfend","ema_product_number":"EMEA/H/C/000387","active_substance":"voriconazole","international_non_proprietary_name_common_name":"voriconazole","therapeutic_area_mesh":"Candidiasis;Mycoses;Aspergillosis","atc_code_human":"J02AC03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Pfizer Europe MA EEIG","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"11/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"19/03/2002","first_published_date":"12/12/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/vfend"},{"category":"Human","name_of_medicine":"Arexvy","ema_product_number":"EMEA/H/C/006054","active_substance":"Respiratory Syncytial Virus recombinant glycoprotein F stabilised in the pre-fusion conformation (RSVPreF3) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology","international_non_proprietary_name_common_name":"recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E","therapeutic_area_mesh":"Respiratory Syncytial Virus Infections","atc_code_human":"J07","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"GlaxoSmithKline Biologicals S.A.","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"11/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"06/06/2023","first_published_date":"12/12/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/arexvy"},{"category":"Human","name_of_medicine":"Winrevair","ema_product_number":"EMEA/H/C/005647","active_substance":"sotatercept","international_non_proprietary_name_common_name":"sotatercept","therapeutic_area_mesh":"Hypertension, Pulmonary","atc_code_human":"C02KX06","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"Yes","prime_priority_medicine":"Yes","marketing_authorisation_developer_applicant_holder":"Merck Sharp & Dohme B.V.","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"11/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"22/08/2024","first_published_date":"12/12/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/winrevair"},{"category":"Human","name_of_medicine":"Dovprela (previously Pretomanid FGK)","ema_product_number":"EMEA/H/C/005167","active_substance":"pretomanid","international_non_proprietary_name_common_name":"pretomanid","therapeutic_area_mesh":"Tuberculosis, Multidrug-Resistant","atc_code_human":"J04","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"Yes","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Mylan IRE Healthcare Limited","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"11/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"31/07/2020","first_published_date":"12/12/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/dovprela-previously-pretomanid-fgk"},{"category":"Human","name_of_medicine":"Elucirem","ema_product_number":"EMEA/H/C/005626","active_substance":"Gadopiclenol","international_non_proprietary_name_common_name":"gadopiclenol","therapeutic_area_mesh":"Magnetic Resonance Imaging","atc_code_human":"V08CA12","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Guerbet","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"11/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"07/12/2023","first_published_date":"12/12/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/elucirem"},{"category":"Human","name_of_medicine":"Vueway","ema_product_number":"EMEA/H/C/006172","active_substance":"Gadopiclenol","international_non_proprietary_name_common_name":"gadopiclenol","therapeutic_area_mesh":"Magnetic Resonance Imaging","atc_code_human":"V08CA12","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Bracco Imaging S.p.A.","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"11/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"07/12/2023","first_published_date":"12/12/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/vueway"},{"category":"Human","name_of_medicine":"Eylea","ema_product_number":"EMEA/H/C/002392","active_substance":"aflibercept","international_non_proprietary_name_common_name":"aflibercept","therapeutic_area_mesh":"Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization","atc_code_human":"S01LA05","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Bayer AG","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"11/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"21/11/2012","first_published_date":"12/12/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/eylea"},{"category":"Human","name_of_medicine":"Nucala","ema_product_number":"EMEA/H/C/003860","active_substance":"Mepolizumab","international_non_proprietary_name_common_name":"mepolizumab","therapeutic_area_mesh":"Asthma","atc_code_human":"R03DX09","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"GlaxoSmithKline Trading Services Limited","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"11/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"01/12/2015","first_published_date":"12/12/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/nucala"},{"category":"Human","name_of_medicine":"Mounjaro","ema_product_number":"EMEA/H/C/005620","active_substance":"tirzepatide","international_non_proprietary_name_common_name":"tirzepatide","therapeutic_area_mesh":"Diabetes Mellitus, Type 2;Obesity;Overweight","atc_code_human":"A10BX16","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Eli Lilly Nederland B.V.","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"11/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"15/09/2022","first_published_date":"12/12/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/mounjaro"},{"category":"Human","name_of_medicine":"Uplizna","ema_product_number":"EMEA/H/C/005818","active_substance":"inebilizumab","international_non_proprietary_name_common_name":"inebilizumab","therapeutic_area_mesh":"Neuromyelitis Optica","atc_code_human":"L04AA","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Amgen Europe B.V.","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"11/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"25/04/2022","first_published_date":"12/12/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/uplizna"},{"category":"Veterinary","name_of_medicine":"Dexdomitor","ema_product_number":"EMEA/V/C/000070","active_substance":"Dexmedetomidine hydrochloride","international_non_proprietary_name_common_name":"dexmedetomidine","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"04/12/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"","first_published_date":"05/12/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/dexdomitor"},{"category":"Human","name_of_medicine":"Brilique","ema_product_number":"EMEA/H/C/001241","active_substance":"ticagrelor","international_non_proprietary_name_common_name":"ticagrelor","therapeutic_area_mesh":"Peripheral Vascular Diseases;Acute Coronary Syndrome","atc_code_human":"B01AC24","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"AstraZeneca AB","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"15/12/2021","marketing_authorisation_date":"03/12/2010","first_published_date":"28/01/2022","last_updated_date":"27/11/2025","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/brilique-0"},{"category":"Veterinary","name_of_medicine":"Vectra 3D","ema_product_number":"EMEA/V/C/002555","active_substance":"dinotefuran;pyriproxyfen;permethrin","international_non_proprietary_name_common_name":"dinotefuran, permethrin, and pyriproxyfen","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"27/11/2024","marketing_authorisation_date":"","first_published_date":"25/11/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/vectra-3d"},{"category":"Human","name_of_medicine":"Xerava","ema_product_number":"EMEA/H/C/004237","active_substance":"eravacycline","international_non_proprietary_name_common_name":"eravacycline","therapeutic_area_mesh":"Infection;Bacterial Infections","atc_code_human":"J01AA","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"PAION Pharma GmbH","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"13/11/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"20/09/2018","first_published_date":"14/11/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/xerava"},{"category":"Human","name_of_medicine":"Minjuvi","ema_product_number":"EMEA/H/C/005436","active_substance":"tafasitamab","international_non_proprietary_name_common_name":"tafasitamab","therapeutic_area_mesh":"Lymphoma, Large B-Cell, Diffuse","atc_code_human":"L01FX12","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"Yes","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"Yes","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Incyte Biosciences Distribution B.V.","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"13/11/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"26/08/2021","first_published_date":"14/11/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/minjuvi"},{"category":"Human","name_of_medicine":"Veyvondi","ema_product_number":"EMEA/H/C/004454","active_substance":"vonicog alfa","international_non_proprietary_name_common_name":"vonicog alfa","therapeutic_area_mesh":"von Willebrand Diseases","atc_code_human":"B02BD10","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Baxalta Innovations GmbH","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"13/11/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"31/08/2018","first_published_date":"14/11/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/veyvondi"},{"category":"Human","name_of_medicine":"Koselugo","ema_product_number":"EMEA/H/C/005244","active_substance":"selumetinib sulfate","international_non_proprietary_name_common_name":"selumetinib","therapeutic_area_mesh":"Neurofibromatosis 1","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"Yes","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"Yes","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"AstraZeneca AB","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"13/11/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"17/06/2021","first_published_date":"14/11/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/koselugo-0"},{"category":"Human","name_of_medicine":"Dupixent","ema_product_number":"EMEA/H/C/004390","active_substance":"dupilumab","international_non_proprietary_name_common_name":"dupilumab","therapeutic_area_mesh":"Dermatitis, Atopic;Prurigo;Esophageal Diseases;Asthma;Sinusitis","atc_code_human":"D11AH05","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Sanofi Winthrop Industrie","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"18/02/2025","marketing_authorisation_date":"26/09/2017","first_published_date":"28/02/2025","last_updated_date":"07/11/2025","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/dupixent-0"},{"category":"Veterinary","name_of_medicine":"Credelio","ema_product_number":"EMEA/V/C/004247","active_substance":"lotilaner","international_non_proprietary_name_common_name":"lotilaner","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"06/11/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"","first_published_date":"07/11/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/credelio"},{"category":"Veterinary","name_of_medicine":"Frontpro (previously Afoxolaner Merial)","ema_product_number":"EMEA/V/C/005126","active_substance":"afoxolaner","international_non_proprietary_name_common_name":"afoxolaner","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"","withdrawal_of_application_date":"","marketing_authorisation_date":"20/05/2019","first_published_date":"07/11/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/frontpro-previously-afoxolaner-merial"},{"category":"Veterinary","name_of_medicine":"Mhyosphere PCV ID","ema_product_number":"EMEA/V/C/005272","active_substance":"Mycoplasma hyopneumoniae, strain 7304 (Nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated","international_non_proprietary_name_common_name":"Mycoplasma hyopneumoniae and porcine circovirus vaccine (inactivated, recombinant)","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"06/11/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"","first_published_date":"07/11/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/mhyosphere-pcv-id"},{"category":"Human","name_of_medicine":"Gazyvaro","ema_product_number":"EMEA/H/C/002799","active_substance":"obinutuzumab","international_non_proprietary_name_common_name":"obinutuzumab","therapeutic_area_mesh":"Leukemia, Lymphocytic, Chronic, B-Cell","atc_code_human":"L01XC15","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Roche Registration GmbH","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"16/10/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"22/07/2014","first_published_date":"17/10/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/gazyvaro-0"},{"category":"Human","name_of_medicine":"Pyrukynd","ema_product_number":"EMEA/H/C/005540","active_substance":"mitapivat sulfate","international_non_proprietary_name_common_name":"mitapivat","therapeutic_area_mesh":"Genetic Diseases, Inborn;Anemia, Hemolytic","atc_code_human":"B06AX04","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"Yes","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Agios Netherlands B.V.","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"16/10/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"09/11/2022","first_published_date":"17/10/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/pyrukynd"},{"category":"Veterinary","name_of_medicine":"Sileo","ema_product_number":"EMEA/V/C/003764","active_substance":"Dexmedetomidine hydrochloride","international_non_proprietary_name_common_name":"dexmedetomidine","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"30/08/2022","marketing_authorisation_date":"","first_published_date":"03/10/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/sileo"},{"category":"Human","name_of_medicine":"Remsima","ema_product_number":"EMEA/H/C/002576","active_substance":"infliximab","international_non_proprietary_name_common_name":"infliximab","therapeutic_area_mesh":"Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Psoriasis;Crohn Disease;Arthritis, Rheumatoid","atc_code_human":"L04AB02","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"Yes","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Celltrion Healthcare Hungary Kft.","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"18/09/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"10/09/2013","first_published_date":"30/09/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/remsima"},{"category":"Human","name_of_medicine":"Koselugo","ema_product_number":"EMEA/H/C/005244","active_substance":"selumetinib sulfate","international_non_proprietary_name_common_name":"selumetinib","therapeutic_area_mesh":"Neurofibromatosis 1","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"Yes","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"Yes","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"AstraZeneca AB","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"18/09/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"17/06/2021","first_published_date":"19/09/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/koselugo"},{"category":"Human","name_of_medicine":"Lunsumio","ema_product_number":"EMEA/H/C/005680","active_substance":"mosunetuzumab","international_non_proprietary_name_common_name":"mosunetuzumab","therapeutic_area_mesh":"Lymphoma, Follicular","atc_code_human":"L01FX25","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"Yes","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"Yes","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Roche Registration GmbH","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"18/09/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"03/06/2022","first_published_date":"19/09/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/lunsumio"},{"category":"Human","name_of_medicine":"Clopidogrel Zentiva (previously Clopidogrel Winthrop)","ema_product_number":"EMEA/H/C/000975","active_substance":"clopidogrel","international_non_proprietary_name_common_name":"clopidogrel","therapeutic_area_mesh":"Stroke;Peripheral Vascular Diseases;Myocardial Infarction;Acute Coronary Syndrome","atc_code_human":"B01AC04","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Zentiva k.s.","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"24/07/2025","withdrawal_of_application_date":"","marketing_authorisation_date":"15/07/2008","first_published_date":"25/07/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/clopidogrel-zentiva-previously-clopidogrel-winthrop"},{"category":"Human","name_of_medicine":"Lutathera","ema_product_number":"EMEA/H/C/004123","active_substance":"lutetium (177Lu) oxodotreotide","international_non_proprietary_name_common_name":"lutetium (177Lu) oxodotreotide","therapeutic_area_mesh":"Neuroendocrine Tumors","atc_code_human":"V10XX04","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"Yes","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Advanced Accelerator Applications","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"09/05/2025","marketing_authorisation_date":"26/09/2017","first_published_date":"23/05/2025","last_updated_date":"27/06/2025","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/lutathera"},{"category":"Human","name_of_medicine":"Inaqovi","ema_product_number":"EMEA/H/C/005823","active_substance":"cedazuridine;decitabine","international_non_proprietary_name_common_name":"cedazuridine;decitabine","therapeutic_area_mesh":"Leukemia, Myeloid","atc_code_human":"L01BC58","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Otsuka Pharmaceutical Netherlands B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"06/11/2024","marketing_authorisation_date":"15/09/2023","first_published_date":"15/11/2024","last_updated_date":"17/06/2025","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/inaqovi"},{"category":"Human","name_of_medicine":"Amyvid","ema_product_number":"EMEA/H/C/002422","active_substance":"florbetapir (18F)","international_non_proprietary_name_common_name":"florbetapir (18F)","therapeutic_area_mesh":"Radionuclide Imaging","atc_code_human":"V09AX05","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Eli Lilly Nederland B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"26/02/2025","marketing_authorisation_date":"14/01/2013","first_published_date":"28/03/2025","last_updated_date":"28/05/2025","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/amyvid"},{"category":"Human","name_of_medicine":"Ngenla","ema_product_number":"EMEA/H/C/005633","active_substance":"somatrogon","international_non_proprietary_name_common_name":"somatrogon","therapeutic_area_mesh":"Growth and Development","atc_code_human":"H01AC08","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"Yes","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Pfizer Europe MA EEIG","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"20/12/2024","marketing_authorisation_date":"14/02/2022","first_published_date":"25/04/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/ngenla"},{"category":"Human","name_of_medicine":"Bimervax","ema_product_number":"EMEA/H/C/006058","active_substance":"SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion dimer produced by recombinant DNA technology","international_non_proprietary_name_common_name":"COVID-19 Vaccine (recombinant, adjuvanted)","therapeutic_area_mesh":"COVID-19 virus infection","atc_code_human":"J07BN","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Hipra Human Health S.L.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"05/02/2025","marketing_authorisation_date":"30/03/2023","first_published_date":"28/02/2025","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/bimervax"},{"category":"Human","name_of_medicine":"Sialanar","ema_product_number":"EMEA/H/C/003883","active_substance":"glycopyrronium bromide","international_non_proprietary_name_common_name":"glycopyrronium bromide","therapeutic_area_mesh":"Sialorrhea","atc_code_human":"A03AB02","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Proveca Pharma Limited","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"06/09/2024","marketing_authorisation_date":"15/09/2016","first_published_date":"20/09/2024","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/sialanar"},{"category":"Human","name_of_medicine":"Tecentriq","ema_product_number":"EMEA/H/C/004143","active_substance":"atezolizumab","international_non_proprietary_name_common_name":"atezolizumab","therapeutic_area_mesh":"Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma","atc_code_human":"L01XC32","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Roche Registration GmbH","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"19/09/2024","withdrawal_of_application_date":"06/09/2024","marketing_authorisation_date":"20/09/2017","first_published_date":"20/09/2024","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/tecentriq-2"},{"category":"Human","name_of_medicine":"Ontilyv","ema_product_number":"EMEA/H/C/005782","active_substance":"opicapone","international_non_proprietary_name_common_name":"opicapone","therapeutic_area_mesh":"Parkinson Disease","atc_code_human":"N04;N04BX04","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Bial Portela & Companhia S.A.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"12/03/2024","marketing_authorisation_date":"21/02/2022","first_published_date":"22/03/2024","last_updated_date":"18/09/2024","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/ontilyv"},{"category":"Human","name_of_medicine":"Ongentys","ema_product_number":"EMEA/H/C/002790","active_substance":"opicapone","international_non_proprietary_name_common_name":"opicapone","therapeutic_area_mesh":"Parkinson Disease","atc_code_human":"N04","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Bial - Portela  Cª, S.A.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"12/03/2024","marketing_authorisation_date":"24/06/2016","first_published_date":"22/03/2024","last_updated_date":"18/09/2024","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/ongentys"},{"category":"Human","name_of_medicine":"Adcetris","ema_product_number":"EMEA/H/C/002455","active_substance":"Brentuximab vedotin","international_non_proprietary_name_common_name":"brentuximab vedotin","therapeutic_area_mesh":"Lymphoma, Non-Hodgkin;Hodgkin Disease","atc_code_human":"L01FX05","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Takeda Pharma A/S","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"23/02/2024","marketing_authorisation_date":"25/10/2012","first_published_date":"22/03/2024","last_updated_date":"18/07/2024","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/adcetris"},{"category":"Human","name_of_medicine":"Scenesse","ema_product_number":"EMEA/H/C/002548","active_substance":"afamelanotide","international_non_proprietary_name_common_name":"afamelanotide","therapeutic_area_mesh":"Protoporphyria, Erythropoietic","atc_code_human":"D02BB02","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"Yes","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Clinuvel Europe Limited","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"24/04/2024","marketing_authorisation_date":"22/12/2014","first_published_date":"31/05/2024","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/scenesse"},{"category":"Human","name_of_medicine":"Orencia","ema_product_number":"EMEA/H/C/000701","active_substance":"abatacept","international_non_proprietary_name_common_name":"abatacept","therapeutic_area_mesh":"Arthritis, Psoriatic;Arthritis, Juvenile Rheumatoid;Arthritis, Rheumatoid","atc_code_human":"L04AA24","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Bristol-Myers Squibb Pharma EEIG","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"19/02/2024","marketing_authorisation_date":"21/05/2007","first_published_date":"22/03/2024","last_updated_date":"30/04/2024","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/orencia"},{"category":"Human","name_of_medicine":"Reyataz","ema_product_number":"EMEA/H/C/000494","active_substance":"atazanavir (as sulfate)","international_non_proprietary_name_common_name":"atazanavir sulfate","therapeutic_area_mesh":"HIV Infections","atc_code_human":"J05AE08","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Bristol-Myers Squibb Pharma EEIG","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"25/04/2024","withdrawal_of_application_date":"","marketing_authorisation_date":"01/03/2004","first_published_date":"26/04/2024","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/reyataz"},{"category":"Human","name_of_medicine":"Iclusig","ema_product_number":"EMEA/H/C/002695","active_substance":"Ponatinib","international_non_proprietary_name_common_name":"ponatinib","therapeutic_area_mesh":"Leukemia, Myeloid;Leukemia, Lymphoid","atc_code_human":"L01EA05","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"Yes","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Incyte Biosciences Distribution B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"11/08/2023","marketing_authorisation_date":"01/07/2013","first_published_date":"14/09/2023","last_updated_date":"30/11/2023","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/iclusig"},{"category":"Human","name_of_medicine":"Bylvay","ema_product_number":"EMEA/H/C/004691","active_substance":"odevixibat","international_non_proprietary_name_common_name":"odevixibat","therapeutic_area_mesh":"Cholestasis, Intrahepatic","atc_code_human":"A05AX","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"Yes","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"Yes","generic_or_hybrid":"No","orphan_medicine":"Yes","prime_priority_medicine":"Yes","marketing_authorisation_developer_applicant_holder":"Ipsen Pharma","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"22/10/2023","marketing_authorisation_date":"16/07/2021","first_published_date":"20/11/2023","last_updated_date":"23/11/2023","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/bylvay-0"},{"category":"Human","name_of_medicine":"Evkeeza","ema_product_number":"EMEA/H/C/005449","active_substance":"Evinacumab","international_non_proprietary_name_common_name":"evinacumab","therapeutic_area_mesh":"Hypercholesterolemia","atc_code_human":"C10AX","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"Yes","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Ultragenyx Germany GmbH","post_authorisation_procedure_status":"Opinion","post_authorisation_opinion_status":"Positive","post_authorisation_opinion_date":"09/11/2023","withdrawal_of_application_date":"","marketing_authorisation_date":"17/06/2021","first_published_date":"10/11/2023","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/evkeeza"},{"category":"Human","name_of_medicine":"RoActemra","ema_product_number":"EMEA/H/C/000955","active_substance":"tocilizumab","international_non_proprietary_name_common_name":"tocilizumab","therapeutic_area_mesh":"Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Cytokine Release Syndrome;Giant Cell Arteritis;COVID-19 virus infection","atc_code_human":"L04AC07","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Roche Registration GmbH","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"13/09/2023","marketing_authorisation_date":"16/01/2009","first_published_date":"13/10/2023","last_updated_date":"07/11/2023","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/roactemra"},{"category":"Human","name_of_medicine":"Gazyvaro","ema_product_number":"EMEA/H/C/002799","active_substance":"obinutuzumab","international_non_proprietary_name_common_name":"obinutuzumab","therapeutic_area_mesh":"Leukemia, Lymphocytic, Chronic, B-Cell","atc_code_human":"L01XC15","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Roche Registration GmbH","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"04/07/2023","marketing_authorisation_date":"22/07/2014","first_published_date":"21/07/2023","last_updated_date":"04/10/2023","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/gazyvaro"},{"category":"Human","name_of_medicine":"Buvidal","ema_product_number":"EMEA/H/C/004651","active_substance":"buprenorphine","international_non_proprietary_name_common_name":"buprenorphine","therapeutic_area_mesh":"Opioid-Related Disorders","atc_code_human":"N07BC01","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Camurus AB","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"13/02/2023","marketing_authorisation_date":"20/11/2018","first_published_date":"24/02/2023","last_updated_date":"14/06/2023","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/buvidal"},{"category":"Human","name_of_medicine":"Ilaris","ema_product_number":"EMEA/H/C/001109","active_substance":"Canakinumab","international_non_proprietary_name_common_name":"canakinumab","therapeutic_area_mesh":"Cryopyrin-Associated Periodic Syndromes;Arthritis, Juvenile Rheumatoid;Arthritis, Gouty","atc_code_human":"L04AC08","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Novartis Europharm Limited","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"26/10/2022","marketing_authorisation_date":"23/10/2009","first_published_date":"11/11/2022","last_updated_date":"23/02/2023","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/ilaris"},{"category":"Human","name_of_medicine":"Gavreto","ema_product_number":"EMEA/H/C/005413","active_substance":"pralsetinib","international_non_proprietary_name_common_name":"pralsetinib","therapeutic_area_mesh":"Carcinoma, Non-Small-Cell Lung","atc_code_human":"L01EX23","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"Yes","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Blueprint Medicines (Netherlands) B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"03/11/2022","marketing_authorisation_date":"18/11/2021","first_published_date":"11/11/2022","last_updated_date":"02/02/2023","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/gavreto"},{"category":"Human","name_of_medicine":"Olumiant","ema_product_number":"EMEA/H/C/004085","active_substance":"Baricitinib","international_non_proprietary_name_common_name":"baricitinib","therapeutic_area_mesh":"Arthritis, Rheumatoid","atc_code_human":"L04AA37","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Eli Lilly Nederland B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"07/12/2022","marketing_authorisation_date":"13/02/2017","first_published_date":"16/12/2022","last_updated_date":"02/02/2023","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/olumiant"},{"category":"Human","name_of_medicine":"Imbruvica","ema_product_number":"EMEA/H/C/003791","active_substance":"Ibrutinib","international_non_proprietary_name_common_name":"ibrutinib","therapeutic_area_mesh":"Lymphoma, Mantle-Cell;Leukemia, Lymphocytic, Chronic, B-Cell","atc_code_human":"L01EL01","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Janssen-Cilag International NV","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"13/12/2022","marketing_authorisation_date":"21/10/2014","first_published_date":"27/01/2023","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/imbruvica"},{"category":"Human","name_of_medicine":"Imcivree","ema_product_number":"EMEA/H/C/005089","active_substance":"setmelanotide","international_non_proprietary_name_common_name":"setmelanotide","therapeutic_area_mesh":"Obesity","atc_code_human":"A08AA","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"Yes","prime_priority_medicine":"Yes","marketing_authorisation_developer_applicant_holder":"Rhythm Pharmaceuticals Netherlands B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"22/04/2022","marketing_authorisation_date":"16/07/2021","first_published_date":"22/07/2022","last_updated_date":"28/09/2022","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/imcivree"},{"category":"Veterinary","name_of_medicine":"Bravecto","ema_product_number":"EMEA/V/C/002526","active_substance":"fluralaner","international_non_proprietary_name_common_name":"fluralaner","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"03/08/2021","marketing_authorisation_date":"","first_published_date":"29/03/2022","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/bravecto"},{"category":"Human","name_of_medicine":"Tookad","ema_product_number":"EMEA/H/C/004182","active_substance":"padeliporfin di-potassium","international_non_proprietary_name_common_name":"padeliporfin","therapeutic_area_mesh":"Prostatic Neoplasms","atc_code_human":"L01XD07","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"STEBA Biotech S.A","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"14/12/2021","marketing_authorisation_date":"10/11/2017","first_published_date":"28/01/2022","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/tookad"},{"category":"Human","name_of_medicine":"Cervarix","ema_product_number":"EMEA/H/C/000721","active_substance":"human papillomavirus1 type 16 L1 protein;human papillomavirus type 18 L1 protein","international_non_proprietary_name_common_name":"human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed)","therapeutic_area_mesh":"Papillomavirus Infections;Uterine Cervical Dysplasia;Immunization","atc_code_human":"J07BM02","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"GlaxoSmithKline Biologicals S.A.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"22/10/2021","marketing_authorisation_date":"20/09/2007","first_published_date":"12/11/2021","last_updated_date":"10/01/2022","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/cervarix"},{"category":"Veterinary","name_of_medicine":"Aivlosin","ema_product_number":"EMEA/V/C/000083","active_substance":"tylvalosin","international_non_proprietary_name_common_name":"tylvalosin","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"17/03/2021","marketing_authorisation_date":"","first_published_date":"07/12/2021","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/aivlosin-0"},{"category":"Human","name_of_medicine":"Tecentriq","ema_product_number":"EMEA/H/C/004143","active_substance":"atezolizumab","international_non_proprietary_name_common_name":"atezolizumab","therapeutic_area_mesh":"Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma","atc_code_human":"L01XC32","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Roche Registration GmbH","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"23/06/2021","marketing_authorisation_date":"20/09/2017","first_published_date":"23/07/2021","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/tecentriq-1"},{"category":"Human","name_of_medicine":"Esbriet","ema_product_number":"EMEA/H/C/002154","active_substance":"Pirfenidone","international_non_proprietary_name_common_name":"pirfenidone","therapeutic_area_mesh":"Idiopathic Pulmonary Fibrosis;Lung Diseases;Respiratory Tract Diseases","atc_code_human":"L04AX05","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Roche Registration GmbH","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"19/05/2021","marketing_authorisation_date":"27/02/2011","first_published_date":"25/06/2021","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/esbriet"},{"category":"Human","name_of_medicine":"Brilique","ema_product_number":"EMEA/H/C/001241","active_substance":"ticagrelor","international_non_proprietary_name_common_name":"ticagrelor","therapeutic_area_mesh":"Peripheral Vascular Diseases;Acute Coronary Syndrome","atc_code_human":"B01AC24","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"AstraZeneca AB","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"05/03/2021","marketing_authorisation_date":"03/12/2010","first_published_date":"26/03/2021","last_updated_date":"25/05/2021","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/brilique"},{"category":"Human","name_of_medicine":"Tecentriq","ema_product_number":"EMEA/H/C/004143","active_substance":"atezolizumab","international_non_proprietary_name_common_name":"atezolizumab","therapeutic_area_mesh":"Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma","atc_code_human":"L01XC32","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Roche Registration GmbH","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"08/01/2021","marketing_authorisation_date":"20/09/2017","first_published_date":"01/02/2021","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/tecentriq-0"},{"category":"Human","name_of_medicine":"Yervoy","ema_product_number":"EMEA/H/C/002213","active_substance":"Ipilimumab","international_non_proprietary_name_common_name":"ipilimumab","therapeutic_area_mesh":"Melanoma;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Mesothelioma, Malignant;Colorectal Neoplasms","atc_code_human":"L01FX04","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Bristol-Myers Squibb Pharma EEIG","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"30/01/2020","marketing_authorisation_date":"13/07/2011","first_published_date":"28/02/2020","last_updated_date":"23/04/2020","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/yervoy"},{"category":"Human","name_of_medicine":"Opdivo","ema_product_number":"EMEA/H/C/003985","active_substance":"nivolumab","international_non_proprietary_name_common_name":"nivolumab","therapeutic_area_mesh":"Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Mesothelioma;Colorectal Neoplasms","atc_code_human":"L01FF01","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Bristol-Myers Squibb Pharma EEIG","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"30/01/2020","marketing_authorisation_date":"19/06/2015","first_published_date":"28/02/2020","last_updated_date":"23/04/2020","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/opdivo-2"},{"category":"Human","name_of_medicine":"Keytruda","ema_product_number":"EMEA/H/C/003820","active_substance":"pembrolizumab","international_non_proprietary_name_common_name":"pembrolizumab","therapeutic_area_mesh":"Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endometrial Neoplasms","atc_code_human":"L01FF02","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Merck Sharp & Dohme B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"10/12/2019","marketing_authorisation_date":"17/07/2015","first_published_date":"31/01/2020","last_updated_date":"19/03/2020","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/keytruda-0"},{"category":"Human","name_of_medicine":"Axumin","ema_product_number":"EMEA/H/C/004197","active_substance":"fluciclovine (18F)","international_non_proprietary_name_common_name":"fluciclovine (18F)","therapeutic_area_mesh":"Prostatic Neoplasms;Radionuclide Imaging","atc_code_human":"V09IX12","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Blue Earth Diagnostics Ireland Ltd","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"11/02/2020","marketing_authorisation_date":"21/05/2017","first_published_date":"28/02/2020","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/axumin"},{"category":"Human","name_of_medicine":"Opsumit","ema_product_number":"EMEA/H/C/002697","active_substance":"macitentan","international_non_proprietary_name_common_name":"macitentan","therapeutic_area_mesh":"Hypertension, Pulmonary","atc_code_human":"C02KX04","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Janssen-Cilag International N.V.  ","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"08/11/2019","marketing_authorisation_date":"20/12/2013","first_published_date":"15/11/2019","last_updated_date":"17/02/2020","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/opsumit"},{"category":"Veterinary","name_of_medicine":"Coliprotec F4/F18","ema_product_number":"EMEA/V/C/004225","active_substance":"Live non-pathogenic Escherichia coli O141:K94 (F18ac) and O8:K87 (F4ac)","international_non_proprietary_name_common_name":"porcine post-weaning diarrhoea vaccine (live)","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"27/05/2019","marketing_authorisation_date":"","first_published_date":"18/09/2019","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/coliprotec-f4-f18"},{"category":"Human","name_of_medicine":"Opdivo","ema_product_number":"EMEA/H/C/003985","active_substance":"nivolumab","international_non_proprietary_name_common_name":"nivolumab","therapeutic_area_mesh":"Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Mesothelioma;Colorectal Neoplasms","atc_code_human":"L01FF01","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Bristol-Myers Squibb Pharma EEIG","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"27/06/2018","marketing_authorisation_date":"19/06/2015","first_published_date":"27/07/2018","last_updated_date":"11/12/2018","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/opdivo-0"},{"category":"Human","name_of_medicine":"Tecentriq","ema_product_number":"EMEA/H/C/004143","active_substance":"atezolizumab","international_non_proprietary_name_common_name":"atezolizumab","therapeutic_area_mesh":"Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma","atc_code_human":"L01XC32","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Roche Registration GmbH","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"22/10/2018","marketing_authorisation_date":"20/09/2017","first_published_date":"16/11/2018","last_updated_date":"","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/tecentriq"},{"category":"Human","name_of_medicine":"Sutent","ema_product_number":"EMEA/H/C/000687","active_substance":"sunitinib","international_non_proprietary_name_common_name":"sunitinib","therapeutic_area_mesh":"Gastrointestinal Stromal Tumors;Carcinoma, Renal Cell;Neuroendocrine Tumors","atc_code_human":"L01EX01","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Pfizer Limited","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"26/06/2018","marketing_authorisation_date":"19/07/2006","first_published_date":"27/07/2018","last_updated_date":"17/08/2018","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/sutent"},{"category":"Human","name_of_medicine":"Qtern","ema_product_number":"EMEA/H/C/004057","active_substance":"saxagliptin;dapagliflozin propanediol monohydrate","international_non_proprietary_name_common_name":"saxagliptin;dapagliflozin","therapeutic_area_mesh":"Diabetes Mellitus, Type 2;Diabetes Mellitus;Nutritional and Metabolic Diseases;Metabolic Diseases;Glucose Metabolism Disorders","atc_code_human":"A10BD21","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Astra Zeneca AB","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"03/04/2018","marketing_authorisation_date":"15/07/2016","first_published_date":"27/04/2018","last_updated_date":"27/04/2018","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/qtern"},{"category":"Human","name_of_medicine":"Aranesp","ema_product_number":"EMEA/H/C/000332","active_substance":"darbepoetin alfa","international_non_proprietary_name_common_name":"darbepoetin alfa","therapeutic_area_mesh":"Anemia;Cancer;Kidney Failure, Chronic","atc_code_human":"B03XA02","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Amgen Europe B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"21/02/2018","marketing_authorisation_date":"08/06/2001","first_published_date":"23/03/2018","last_updated_date":"24/04/2018","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/aranesp"},{"category":"Human","name_of_medicine":"Zydelig","ema_product_number":"EMEA/H/C/003843","active_substance":"Idelalisib","international_non_proprietary_name_common_name":"idelalisib","therapeutic_area_mesh":"Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, Chronic, B-Cell","atc_code_human":"L01XX47","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Gilead Sciences Ireland UC","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"30/01/2018","marketing_authorisation_date":"18/09/2014","first_published_date":"23/02/2018","last_updated_date":"23/02/2018","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/zydelig"},{"category":"Human","name_of_medicine":"Opdivo","ema_product_number":"EMEA/H/C/003985","active_substance":"nivolumab","international_non_proprietary_name_common_name":"nivolumab","therapeutic_area_mesh":"Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Mesothelioma;Colorectal Neoplasms","atc_code_human":"L01FF01","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Bristol-Myers Squibb Pharma EEIG","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"13/12/2017","marketing_authorisation_date":"19/06/2015","first_published_date":"26/01/2018","last_updated_date":"26/01/2018","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/opdivo-1"},{"category":"Human","name_of_medicine":"Opdivo","ema_product_number":"EMEA/H/C/003985","active_substance":"nivolumab","international_non_proprietary_name_common_name":"nivolumab","therapeutic_area_mesh":"Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Mesothelioma;Colorectal Neoplasms","atc_code_human":"L01FF01","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Bristol-Myers Squibb Pharma EEIG","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"20/07/2017","marketing_authorisation_date":"19/06/2015","first_published_date":"15/09/2017","last_updated_date":"06/12/2017","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/opdivo"},{"category":"Human","name_of_medicine":"Keytruda","ema_product_number":"EMEA/H/C/003820","active_substance":"pembrolizumab","international_non_proprietary_name_common_name":"pembrolizumab","therapeutic_area_mesh":"Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endometrial Neoplasms","atc_code_human":"L01FF02","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Merck Sharp & Dohme B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"11/10/2017","marketing_authorisation_date":"17/07/2015","first_published_date":"10/11/2017","last_updated_date":"28/11/2017","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/keytruda"},{"category":"Human","name_of_medicine":"Xgeva","ema_product_number":"EMEA/H/C/002173","active_substance":"denosumab","international_non_proprietary_name_common_name":"denosumab","therapeutic_area_mesh":"Giant Cell Tumor of Bone;Neoplasms, Bone Tissue","atc_code_human":"M05BX04","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Amgen Europe B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"13/01/2017","marketing_authorisation_date":"13/07/2011","first_published_date":"27/01/2017","last_updated_date":"05/05/2017","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/xgeva"},{"category":"Human","name_of_medicine":"Translarna","ema_product_number":"EMEA/H/C/002720","active_substance":"ataluren","international_non_proprietary_name_common_name":"ataluren","therapeutic_area_mesh":"Muscular Dystrophy, Duchenne","atc_code_human":"M09AX03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"Yes","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"PTC Therapeutics International Limited","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"06/03/2017","marketing_authorisation_date":"31/07/2014","first_published_date":"24/03/2017","last_updated_date":"24/03/2017","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/translarna"},{"category":"Human","name_of_medicine":"Arzerra","ema_product_number":"EMEA/H/C/001131","active_substance":"ofatumumab","international_non_proprietary_name_common_name":"ofatumumab","therapeutic_area_mesh":"Leukemia, Lymphocytic, Chronic, B-Cell","atc_code_human":"L01XC10","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Novartis Europharm Ltd","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"08/11/2016","marketing_authorisation_date":"19/04/2010","first_published_date":"16/12/2016","last_updated_date":"16/12/2016","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/arzerra"},{"category":"Human","name_of_medicine":"Adempas","ema_product_number":"EMEA/H/C/002737","active_substance":"riociguat","international_non_proprietary_name_common_name":"riociguat","therapeutic_area_mesh":"Hypertension, Pulmonary","atc_code_human":"C02KX05","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Bayer AG","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"11/08/2016","marketing_authorisation_date":"27/03/2014","first_published_date":"16/09/2016","last_updated_date":"16/09/2016","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/adempas"},{"category":"Human","name_of_medicine":"Rienso","ema_product_number":"EMEA/H/C/002215","active_substance":"Ferumoxytol","international_non_proprietary_name_common_name":"ferumoxytol","therapeutic_area_mesh":"Anemia;Kidney Failure, Chronic","atc_code_human":"B03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Takeda Pharma A/S","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"19/01/2015","marketing_authorisation_date":"15/06/2012","first_published_date":"27/02/2015","last_updated_date":"27/02/2015","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/rienso"},{"category":"Human","name_of_medicine":"Teysuno","ema_product_number":"EMEA/H/C/001242","active_substance":"tegafur;gimeracil;oteracil","international_non_proprietary_name_common_name":"tegafur;gimeracil;oteracil","therapeutic_area_mesh":"Stomach Neoplasms","atc_code_human":"L01BC53","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Nordic Group B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"06/01/2015","marketing_authorisation_date":"14/03/2011","first_published_date":"23/01/2015","last_updated_date":"23/01/2015","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/teysuno"},{"category":"Human","name_of_medicine":"Somavert","ema_product_number":"EMEA/H/C/000409","active_substance":"pegvisomant","international_non_proprietary_name_common_name":"pegvisomant","therapeutic_area_mesh":"Acromegaly","atc_code_human":"H01AX01","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Pfizer Europe MA EEIG","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"16/02/2012","marketing_authorisation_date":"12/11/2002","first_published_date":"19/09/2014","last_updated_date":"19/09/2014","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/somavert"},{"category":"Veterinary","name_of_medicine":"Aivlosin","ema_product_number":"EMEA/V/C/000083","active_substance":"tylvalosin","international_non_proprietary_name_common_name":"tylvalosin","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"06/01/2014","marketing_authorisation_date":"","first_published_date":"21/07/2014","last_updated_date":"21/07/2014","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/aivlosin"},{"category":"Human","name_of_medicine":"Simponi","ema_product_number":"EMEA/H/C/000992","active_substance":"golimumab","international_non_proprietary_name_common_name":"golimumab","therapeutic_area_mesh":"Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Arthritis, Rheumatoid","atc_code_human":"L04AB06","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Janssen Cilag International NV","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"12/05/2014","marketing_authorisation_date":"01/10/2009","first_published_date":"15/07/2014","last_updated_date":"15/07/2014","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/simponi"},{"category":"Human","name_of_medicine":"Osseor","ema_product_number":"EMEA/H/C/000561","active_substance":"strontium ranelate","international_non_proprietary_name_common_name":"strontium ranelate","therapeutic_area_mesh":"Osteoporosis, Postmenopausal","atc_code_human":"M05BX03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Les Laboratoires Servier","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"21/03/2014","marketing_authorisation_date":"20/09/2004","first_published_date":"23/05/2014","last_updated_date":"01/07/2014","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/osseor"},{"category":"Human","name_of_medicine":"Protelos","ema_product_number":"EMEA/H/C/000560","active_substance":"strontium ranelate","international_non_proprietary_name_common_name":"strontium ranelate","therapeutic_area_mesh":"Osteoporosis, Postmenopausal","atc_code_human":"M05BX03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Les Laboratoires Servier","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"21/03/2014","marketing_authorisation_date":"20/09/2004","first_published_date":"23/05/2014","last_updated_date":"01/07/2014","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/protelos"},{"category":"Human","name_of_medicine":"Tasigna","ema_product_number":"EMEA/H/C/000798","active_substance":"nilotinib","international_non_proprietary_name_common_name":"nilotinib","therapeutic_area_mesh":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","atc_code_human":"L01EA03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Novartis Europharm Limited","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"21/05/2014","marketing_authorisation_date":"19/11/2007","first_published_date":"27/06/2014","last_updated_date":"27/06/2014","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/tasigna"},{"category":"Human","name_of_medicine":"Votrient","ema_product_number":"EMEA/H/C/001141","active_substance":"pazopanib","international_non_proprietary_name_common_name":"pazopanib","therapeutic_area_mesh":"Carcinoma, Renal Cell","atc_code_human":"L01XE11","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Novartis Europharm Limited ","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"27/03/2014","marketing_authorisation_date":"14/06/2010","first_published_date":"25/04/2014","last_updated_date":"25/04/2014","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/votrient"},{"category":"Human","name_of_medicine":"Firazyr","ema_product_number":"EMEA/H/C/000899","active_substance":"icatibant","international_non_proprietary_name_common_name":"icatibant","therapeutic_area_mesh":"Angioedemas, Hereditary","atc_code_human":"B06AC02","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Takeda Pharmaceuticals International AG","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"14/02/2014","marketing_authorisation_date":"11/07/2008","first_published_date":"21/02/2014","last_updated_date":"21/02/2014","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/firazyr"},{"category":"Human","name_of_medicine":"Prometax","ema_product_number":"EMEA/H/C/000255","active_substance":"rivastigmine","international_non_proprietary_name_common_name":"rivastigmine","therapeutic_area_mesh":"Alzheimer Disease;Parkinson Disease;Dementia","atc_code_human":"N06DA03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Almirall, S.A.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"21/11/2013","marketing_authorisation_date":"04/12/1998","first_published_date":"20/12/2013","last_updated_date":"18/02/2014","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/prometax"},{"category":"Human","name_of_medicine":"Exelon","ema_product_number":"EMEA/H/C/000169","active_substance":"rivastigmine","international_non_proprietary_name_common_name":"rivastigmine","therapeutic_area_mesh":"Dementia;Alzheimer Disease;Parkinson Disease","atc_code_human":"N06DA03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Novartis Europharm Limited","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"21/11/2013","marketing_authorisation_date":"11/05/1998","first_published_date":"20/12/2013","last_updated_date":"18/02/2014","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/exelon-0"},{"category":"Human","name_of_medicine":"Ceprotin","ema_product_number":"EMEA/H/C/000334","active_substance":"human protein C","international_non_proprietary_name_common_name":"human protein C","therapeutic_area_mesh":"Purpura Fulminans;Protein C Deficiency","atc_code_human":"B01AD12","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Takeda Manufacturing Austria AG","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"22/10/2014","marketing_authorisation_date":"16/07/2001","first_published_date":"21/11/2013","last_updated_date":"21/11/2013","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/ceprotin"},{"category":"Human","name_of_medicine":"Effentora","ema_product_number":"EMEA/H/C/000833","active_substance":"fentanyl","international_non_proprietary_name_common_name":"fentanyl","therapeutic_area_mesh":"Pain;Cancer","atc_code_human":"N02AB03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Teva B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"11/07/2013","marketing_authorisation_date":"04/04/2008","first_published_date":"26/07/2013","last_updated_date":"29/08/2013","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/effentora"},{"category":"Human","name_of_medicine":"Eviplera","ema_product_number":"EMEA/H/C/002312","active_substance":"emtricitabine;rilpivirine hydrochloride;tenofovir disoproxil fumarate","international_non_proprietary_name_common_name":"emtricitabine;rilpivirine;tenofovir disoproxil","therapeutic_area_mesh":"HIV Infections","atc_code_human":"J05AR08","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Gilead Sciences International Ltd ","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"16/07/2013","marketing_authorisation_date":"27/11/2011","first_published_date":"26/07/2013","last_updated_date":"26/07/2013","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/eviplera"},{"category":"Human","name_of_medicine":"Tysabri","ema_product_number":"EMEA/H/C/000603","active_substance":"natalizumab","international_non_proprietary_name_common_name":"natalizumab","therapeutic_area_mesh":"Multiple Sclerosis","atc_code_human":"L04AG03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Biogen Netherlands B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"14/05/2013","marketing_authorisation_date":"27/06/2006","first_published_date":"31/05/2013","last_updated_date":"31/05/2013","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/tysabri"},{"category":"Veterinary","name_of_medicine":"Zolvix","ema_product_number":"EMEA/V/C/000154","active_substance":"monepantel","international_non_proprietary_name_common_name":"monepantel","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"19/10/2012","marketing_authorisation_date":"","first_published_date":"25/01/2013","last_updated_date":"25/01/2013","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/zolvix"},{"category":"Human","name_of_medicine":"Erbitux","ema_product_number":"EMEA/H/C/000558","active_substance":"cetuximab","international_non_proprietary_name_common_name":"cetuximab","therapeutic_area_mesh":"Head and Neck Neoplasms;Colorectal Neoplasms","atc_code_human":"L01FE01","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Merck Europe B.V. ","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"17/09/2012","marketing_authorisation_date":"29/06/2004","first_published_date":"12/10/2012","last_updated_date":"22/11/2012","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/erbitux"},{"category":"Human","name_of_medicine":"Velcade","ema_product_number":"EMEA/H/C/000539","active_substance":"bortezomib","international_non_proprietary_name_common_name":"bortezomib","therapeutic_area_mesh":"Multiple Myeloma","atc_code_human":"L01XG01","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Janssen-Cilag International NV","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"02/07/2012","marketing_authorisation_date":"26/04/2004","first_published_date":"31/07/2012","last_updated_date":"30/08/2012","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/velcade"},{"category":"Human","name_of_medicine":"Revlimid","ema_product_number":"EMEA/H/C/000717","active_substance":"lenalidomide","international_non_proprietary_name_common_name":"lenalidomide","therapeutic_area_mesh":"Multiple Myeloma;Lymphoma, Mantle-Cell;Myelodysplastic Syndromes","atc_code_human":"L04AX04","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Bristol-Myers Squibb Pharma EEIG","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"20/06/2012","marketing_authorisation_date":"14/06/2007","first_published_date":"06/07/2012","last_updated_date":"06/07/2012","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/revlimid"},{"category":"Veterinary","name_of_medicine":"Draxxin","ema_product_number":"EMEA/V/C/000077","active_substance":"tulathromycin","international_non_proprietary_name_common_name":"tulathromycin","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"11/05/2012","marketing_authorisation_date":"","first_published_date":"04/07/2012","last_updated_date":"04/07/2012","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/draxxin"},{"category":"Human","name_of_medicine":"Prometax","ema_product_number":"EMEA/H/C/000255","active_substance":"rivastigmine","international_non_proprietary_name_common_name":"rivastigmine","therapeutic_area_mesh":"Alzheimer Disease;Parkinson Disease;Dementia","atc_code_human":"N06DA03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Almirall, S.A.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"14/03/2012","marketing_authorisation_date":"04/12/1998","first_published_date":"19/04/2012","last_updated_date":"19/04/2012","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/prometax-0"},{"category":"Human","name_of_medicine":"Exelon","ema_product_number":"EMEA/H/C/000169","active_substance":"rivastigmine","international_non_proprietary_name_common_name":"rivastigmine","therapeutic_area_mesh":"Dementia;Alzheimer Disease;Parkinson Disease","atc_code_human":"N06DA03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Novartis Europharm Limited","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"14/03/2012","marketing_authorisation_date":"11/05/1998","first_published_date":"19/04/2012","last_updated_date":"19/04/2012","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/exelon"},{"category":"Human","name_of_medicine":"Qutenza","ema_product_number":"EMEA/H/C/000909","active_substance":"capsaicin","international_non_proprietary_name_common_name":"capsaicin","therapeutic_area_mesh":"Neuralgia","atc_code_human":"N01BX04","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Grunenthal GmbH","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"14/03/2012","marketing_authorisation_date":"15/05/2009","first_published_date":"16/04/2012","last_updated_date":"16/04/2012","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/qutenza"},{"category":"Human","name_of_medicine":"Tyverb","ema_product_number":"EMEA/H/C/000795","active_substance":"lapatinib","international_non_proprietary_name_common_name":"lapatinib","therapeutic_area_mesh":"Breast Neoplasms","atc_code_human":"L01EH01","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Novartis Europharm Limited","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"15/02/2012","marketing_authorisation_date":"10/06/2008","first_published_date":"16/03/2012","last_updated_date":"16/03/2012","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/tyverb"},{"category":"Human","name_of_medicine":"Macugen","ema_product_number":"EMEA/H/C/000620","active_substance":"pegaptanib","international_non_proprietary_name_common_name":"pegaptanib","therapeutic_area_mesh":"Wet Macular Degeneration","atc_code_human":"S01LA03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"PharmaSwiss Ceska Republika s.r.o","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"15/07/2011","marketing_authorisation_date":"31/01/2006","first_published_date":"27/07/2011","last_updated_date":"27/07/2011","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/macugen"},{"category":"Human","name_of_medicine":"Zometa","ema_product_number":"EMEA/H/C/000336","active_substance":"zoledronic acid;zoledronic acid monohydrate","international_non_proprietary_name_common_name":"zoledronic acid","therapeutic_area_mesh":"Cancer;Fractures, Bone","atc_code_human":"M05BA08","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Phoenix Labs Unlimited Company","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"14/12/2010","marketing_authorisation_date":"20/03/2001","first_published_date":"25/01/2011","last_updated_date":"01/01/2011","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/zometa-0"},{"category":"Human","name_of_medicine":"Intrinsa","ema_product_number":"EMEA/H/C/000634","active_substance":"testosterone","international_non_proprietary_name_common_name":"testosterone","therapeutic_area_mesh":"Sexual Dysfunctions, Psychological","atc_code_human":"G03BA03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Warner Chilcott UK Ltd.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"29/09/2010","marketing_authorisation_date":"28/07/2006","first_published_date":"29/09/2010","last_updated_date":"29/09/2010","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/intrinsa"},{"category":"Veterinary","name_of_medicine":"Naxcel","ema_product_number":"EMEA/V/C/000079","active_substance":"ceftiofur","international_non_proprietary_name_common_name":"ceftiofur","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"04/02/2010","marketing_authorisation_date":"","first_published_date":"23/06/2010","last_updated_date":"23/06/2010","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/naxcel"},{"category":"Human","name_of_medicine":"Abilify","ema_product_number":"EMEA/H/C/000471","active_substance":"aripiprazole","international_non_proprietary_name_common_name":"aripiprazole","therapeutic_area_mesh":"Schizophrenia;Bipolar Disorder","atc_code_human":"N05AX12","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Otsuka Pharmaceutical Netherlands B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"17/11/2009","marketing_authorisation_date":"04/06/2004","first_published_date":"19/11/2009","last_updated_date":"19/11/2009","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/abilify"},{"category":"Human","name_of_medicine":"Stalevo","ema_product_number":"EMEA/H/C/000511","active_substance":"levodopa;carbidopa;entacapone","international_non_proprietary_name_common_name":"levodopa;carbidopa;entacapone","therapeutic_area_mesh":"Parkinson Disease","atc_code_human":"N04BA03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Orion Corporation","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"06/03/2009","marketing_authorisation_date":"17/10/2003","first_published_date":"10/03/2009","last_updated_date":"10/03/2009","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/stalevo"},{"category":"Veterinary","name_of_medicine":"Zubrin","ema_product_number":"EMEA/V/C/000057","active_substance":"tepoxalin","international_non_proprietary_name_common_name":"tepoxalin","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"QM01AE92","species_veterinary":"Dogs","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Intervet International BV","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"03/10/2008","marketing_authorisation_date":"13/03/2001","first_published_date":"24/02/2009","last_updated_date":"24/02/2009","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/zubrin"},{"category":"Human","name_of_medicine":"Invega","ema_product_number":"EMEA/H/C/000746","active_substance":"paliperidone","international_non_proprietary_name_common_name":"paliperidone","therapeutic_area_mesh":"Schizophrenia;Psychotic Disorders","atc_code_human":"N05AX13","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Janssen-Cilag International NV","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"15/12/2008","marketing_authorisation_date":"24/06/2007","first_published_date":"17/12/2008","last_updated_date":"17/12/2008","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/invega"},{"category":"Human","name_of_medicine":"Viagra","ema_product_number":"EMEA/H/C/000202","active_substance":"sildenafil","international_non_proprietary_name_common_name":"sildenafil","therapeutic_area_mesh":"Erectile Dysfunction","atc_code_human":"G04BE03","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Upjohn EESV","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"19/11/2008","marketing_authorisation_date":"13/09/1998","first_published_date":"20/11/2008","last_updated_date":"20/11/2008","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/viagra"},{"category":"Human","name_of_medicine":"Taxotere","ema_product_number":"EMEA/H/C/000073","active_substance":"docetaxel","international_non_proprietary_name_common_name":"docetaxel","therapeutic_area_mesh":"Head and Neck Neoplasms;Carcinoma, Non-Small-Cell Lung;Adenocarcinoma;Prostatic Neoplasms;Stomach Neoplasms;Breast Neoplasms","atc_code_human":"L01CD02","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Sanofi Winthrop Industrie","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"14/11/2008","marketing_authorisation_date":"27/11/1995","first_published_date":"17/11/2008","last_updated_date":"17/11/2008","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/taxotere"},{"category":"Human","name_of_medicine":"Docetaxel Zentiva (previously Docetaxel Winthrop)","ema_product_number":"EMEA/H/C/000808","active_substance":"docetaxel","international_non_proprietary_name_common_name":"docetaxel","therapeutic_area_mesh":"Head and Neck Neoplasms;Carcinoma, Non-Small-Cell Lung;Adenocarcinoma;Prostatic Neoplasms;Stomach Neoplasms;Breast Neoplasms","atc_code_human":"L01CD02","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Zentiva k.s.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"14/11/2008","marketing_authorisation_date":"20/04/2007","first_published_date":"17/11/2008","last_updated_date":"17/11/2008","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/docetaxel-zentiva-previously-docetaxel-winthrop"},{"category":"Human","name_of_medicine":"Tygacil","ema_product_number":"EMEA/H/C/000644","active_substance":"tigecycline","international_non_proprietary_name_common_name":"tigecycline","therapeutic_area_mesh":"Bacterial Infections;Skin Diseases, Bacterial;Soft Tissue Infections","atc_code_human":"J01AA12","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Pfizer Europe MA EEIG","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"22/04/2008","marketing_authorisation_date":"24/04/2006","first_published_date":"24/04/2008","last_updated_date":"24/04/2008","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/tygacil"},{"category":"Human","name_of_medicine":"Evoltra","ema_product_number":"EMEA/H/C/000613","active_substance":"clofarabine","international_non_proprietary_name_common_name":"clofarabine","therapeutic_area_mesh":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","atc_code_human":"L01BB06","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"Yes","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"Yes","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Sanofi B.V.","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"18/03/2008","marketing_authorisation_date":"29/05/2006","first_published_date":"19/03/2008","last_updated_date":"19/03/2008","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/evoltra"},{"category":"Human","name_of_medicine":"Zavesca","ema_product_number":"EMEA/H/C/000435","active_substance":"miglustat","international_non_proprietary_name_common_name":"miglustat","therapeutic_area_mesh":"Gaucher Disease;Niemann-Pick Diseases","atc_code_human":"A16AX06","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Janssen Cilag International NV","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"19/02/2008","marketing_authorisation_date":"20/11/2002","first_published_date":"25/02/2008","last_updated_date":"25/02/2008","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/zavesca"},{"category":"Human","name_of_medicine":"NutropinAq","ema_product_number":"EMEA/H/C/000315","active_substance":"somatropin","international_non_proprietary_name_common_name":"somatropin","therapeutic_area_mesh":"Turner Syndrome;Dwarfism, Pituitary","atc_code_human":"H01AC01","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Ipsen Pharma","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"24/01/2008","marketing_authorisation_date":"15/02/2001","first_published_date":"28/01/2008","last_updated_date":"28/01/2008","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/nutropinaq"},{"category":"Human","name_of_medicine":"Zometa","ema_product_number":"EMEA/H/C/000336","active_substance":"zoledronic acid;zoledronic acid monohydrate","international_non_proprietary_name_common_name":"zoledronic acid","therapeutic_area_mesh":"Cancer;Fractures, Bone","atc_code_human":"M05BA08","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Phoenix Labs Unlimited Company","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"15/11/2007","marketing_authorisation_date":"20/03/2001","first_published_date":"20/11/2007","last_updated_date":"20/11/2007","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/zometa"},{"category":"Veterinary","name_of_medicine":"Draxxin","ema_product_number":"EMEA/V/C/000077","active_substance":"tulathromycin","international_non_proprietary_name_common_name":"tulathromycin","therapeutic_area_mesh":"","atc_code_human":"","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"17/01/2007","marketing_authorisation_date":"","first_published_date":"17/01/2007","last_updated_date":"17/01/2007","medicine_url":"https://www.ema.europa.eu/en/medicines/veterinary/variation/draxxin-0"},{"category":"Human","name_of_medicine":"Glivec","ema_product_number":"EMEA/H/C/000406","active_substance":"imatinib","international_non_proprietary_name_common_name":"imatinib","therapeutic_area_mesh":"Precursor Cell Lymphoblastic Leukemia-Lymphoma;Gastrointestinal Stromal Tumors;Dermatofibrosarcoma;Myelodysplastic-Myeloproliferative Diseases;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Hypereosinophilic Syndrome","atc_code_human":"L01EA01","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Novartis Europharm Limited","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"18/10/2006","marketing_authorisation_date":"07/11/2001","first_published_date":"23/10/2006","last_updated_date":"23/10/2006","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/glivec"},{"category":"Human","name_of_medicine":"NovoNorm","ema_product_number":"EMEA/H/C/000187","active_substance":"repaglinide","international_non_proprietary_name_common_name":"repaglinide","therapeutic_area_mesh":"Diabetes Mellitus, Type 2","atc_code_human":"A10BX02","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Novo Nordisk A/S","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"12/10/2006","marketing_authorisation_date":"16/08/1998","first_published_date":"13/10/2006","last_updated_date":"13/10/2006","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/novonorm"},{"category":"Human","name_of_medicine":"Prandin","ema_product_number":"EMEA/H/C/000362","active_substance":"repaglinide","international_non_proprietary_name_common_name":"repaglinide","therapeutic_area_mesh":"Diabetes Mellitus, Type 2","atc_code_human":"A10BX02","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Novo Nordisk A/S","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"12/10/2006","marketing_authorisation_date":"29/01/2001","first_published_date":"13/10/2006","last_updated_date":"13/10/2006","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/prandin"},{"category":"Human","name_of_medicine":"DepoCyte","ema_product_number":"EMEA/H/C/000317","active_substance":"cytarabine","international_non_proprietary_name_common_name":"cytarabine","therapeutic_area_mesh":"Meningeal Neoplasms","atc_code_human":"L01BC01","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Pacira Limited","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"28/06/2006","marketing_authorisation_date":"11/07/2001","first_published_date":"30/06/2006","last_updated_date":"30/06/2006","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/depocyte"},{"category":"Human","name_of_medicine":"NovoSeven","ema_product_number":"EMEA/H/C/000074","active_substance":"eptacog alfa (activated)","international_non_proprietary_name_common_name":"eptacog alfa (activated)","therapeutic_area_mesh":"Hemophilia B;Thrombasthenia;Factor VII Deficiency;Hemophilia A","atc_code_human":"B02BD08","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Novo Nordisk A/S","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"03/04/2006","marketing_authorisation_date":"23/02/1996","first_published_date":"06/04/2006","last_updated_date":"06/04/2006","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/novoseven"},{"category":"Human","name_of_medicine":"Opatanol","ema_product_number":"EMEA/H/C/000407","active_substance":"olopatadine hydrochloride","international_non_proprietary_name_common_name":"olopatadine","therapeutic_area_mesh":"Conjunctivitis, Allergic","atc_code_human":"S01GX09","atcvet_code_veterinary":"","species_veterinary":"","accelerated_assessment":"No","additional_monitoring":"No","advanced_therapy":"No","biosimilar":"No","conditional_approval":"No","exceptional_circumstances":"No","generic_or_hybrid":"No","orphan_medicine":"No","prime_priority_medicine":"No","marketing_authorisation_developer_applicant_holder":"Novartis Europharm Limited","post_authorisation_procedure_status":"Application withdrawn","post_authorisation_opinion_status":"","post_authorisation_opinion_date":"","withdrawal_of_application_date":"14/02/2006","marketing_authorisation_date":"16/05/2002","first_published_date":"23/02/2006","last_updated_date":"23/02/2006","medicine_url":"https://www.ema.europa.eu/en/medicines/human/variation/opatanol"}]